Skip to main content

Market Overview

Vitiligo Pipeline - Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight

Share:

Los Angeles, June 03, 2021 (GLOBE NEWSWIRE) -- Vitiligo Pipeline - Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight

Prominent companies such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others are developing potential drug candidates to boost the Vitiligo treatment scenario. Out of all the emerging therapies, the late-stage product Ruxolitinib has shown promising results and will have a major impact on the Vitiligo treatment market.

DelveInsight's Vitiligo Pipeline Insights' report offers a holistic coverage of the current treatments and pipeline therapies and landscape in different stages of development from pre-clinical till late-stage, along with dormant, inactive and abandoned therapeutic agents. 

Some of the key pointers from the Vitiligo Pipeline report:

  • Vitiligo Pipeline report offers a rich analysis of 20+ key players actively working in the space developing over 20+ key therapies 
  • Vitiligo pipeline comprises therapies in different stages of trials such as Cerdulatinib, Ruxolitinib, AC-1101, ATI-1777, QLT-450, AMG 714, PF-06651600, ANB030, ARQ-252, BNZ-1, TT-01, and others.
  • Key pharma companies involved in accelerating the drug development for Vitiligo include Dermavant Sciences, Incyte Corporation, TWi Biotechnology, Aclaris Therapeutics, Dermira, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, Bioniz Therapeutics, among others. 
  • DelveInsight estimates that the late-stage product Ruxolitinib (Incyte Corporation) is expected to have a major impact on the vitiligo treatment market owing to its immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. Incyte Corporation plans to submit regulatory applications for Vitiligo (In children, In adolescent, In adults) in the USA and European Union, in the second half of 2021
  • In March 2020, Edesa Biotech entered into a collaborative research agreement with the National Research Council (NRC) of Canada for the development of monoclonal antibody candidates for vitiligo as well as other autoimmune diseases. Under the terms of the agreement, multiple monoclonal antibodies will be produced by the National Research Council of Canada from which Edesa will identify a lead candidate to take into IND-enabling studies. The NRC will grant an exclusive worldwide license for the antibodies arising from the project to Edesa.
  • In January 2020, Eli Lilly and Company announced a definitive agreement to acquire Dermira for approximately $1.1 billion, in an all-cash transaction. Dermira is a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions such as acne, atopic dermatitis, and Vitiligo.
  • Arcutis Biotherapeutics in-licensed SHR0302, the active ingredient in ARQ-252, a potent and highly selective inhibitor of janus kinase type 1 (JAK1), from a Chinese company Jiangsu Hengrui Medicine Co. Many signalling molecules rely on the JAK pathway — especially JAK1 — which plays a central role in immune system function. Arcutis believes this compound has a promising treatment potential without hematopoietic adverse effects typically associated with JAK2 inhibition. Arcutis initiated a Phase 2a study in March 2021 to evaluate ARQ-252 as a potential treatment for vitiligo. 
  • AnaptysBio with its ANB030 (Anti-PD-1 Agonist) program is moving into a healthy volunteer Phase 1 trial, with top-line data anticipated in mid-2021. If all goes well, Phase 2 clinical trials in alopecia areata and vitiligo are scheduled for Q4 2021.

Request for Sample to know more about the key pharma company and therapy expected to grab maximum share @ Vitiligo Emerging Therapies and Forecast 

The Vitiligo Pipeline reports a panoramic view of the ongoing clinical trials, mergers & partnerships taking place in the domain, recent happenings in space and growth prospects across the Vitiligo domain that continue to attract the pharma companies.

Vitiligo: Overview

Vitiligo is a complex pigment disorder that affects the skin, hair, and occasionally the mucous membranes leading to the development of white patches and discoloration. The condition is due to a lack of pigment melanin that is produced by the skin cells known as melanocytes. 

For more information on emerging drugs, visit Vitiligo Pipeline Analysis 

Vitiligo Drug Pipeline Assessment

Drug Company Phase MoA RoA
Cerdulatinib Dermavant Sciences  Phase II Janus kinase inhibitors; Syk kinase inhibitors Topical
Ruxolitinib Incyte Corporation Phase III Janus kinase 1 inhibitors; Janus kinase-2 inhibitors Topical
AC-1101 TWi Biotechnology Phase I Janus kinase 1 inhibitors; Janus kinase 3 inhibitors Topical
ATI-1777 Aclaris Therapeutics Preclinical Janus kinase 1 inhibitors; Janus kinase 3 inhibitors Topical
QLT-450 Dermira Preclinical Enzyme inhibitors; Protein kinase inhibitors NA
AMG 714 Amgen Phase II Interleukin 15 inhibitors Subcutaneous
PF-06651600 Pfizer Phase II Emt protein-tyrosine kinase inhibitors; Janus kinase 3 inhibitors Oral
ARQ-252 Arcutis Biotherapeutics Phase II Janus kinase 1 inhibitors Topical

Request for Sample to know more @ Vitiligo Pipeline Analysis, Key Companies and Futuristic Trends 

Vitiligo Therapeutics Assessment 

The Vitiligo Pipeline report proffers comprehensive coverage of the active pipeline candidates segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Molecule Type 

  • Gene therapies
  • Small molecule
  • Peptides
  • Monoclonal antibodies

By Route of Administration

  • Oral
  • Subcutaneous
  • Topical

By Mechanism of Action

  • Janus kinase 1 inhibitors
  • Janus kinase-2 inhibitors
  • Emt protein-tyrosine kinase inhibitors
  • Syk kinase inhibitors
  • Janus kinase 3 inhibitors
  • Interleukin 15 inhibitors
  • Protein kinase inhibitors

By Targets

  • Janus kinase 1
  • Janus kinase-2
  • Janus kinase 3
  • Emt protein-tyrosine kinase
  • Interleukin 15
  • Syk kinase

Connect with our Business Executive for Asset Prioritization Services and Consulting Solutions 

Scope of the Vitiligo Pipeline Report

Coverage: Global
Key Players: Dermavant Sciences, Incyte Corporation, TWi Biotechnology, Aclaris Therapeutics, Dermira, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, Bioniz Therapeutics, and others. 
Key Vitiligo Pipeline Therapies: Cerdulatinib, Ruxolitinib, Brepocitinib, AC-1101, ATI-1777, QLT-450, AMG 714, PF-06651600, ANB030, ARQ-252, BNZ-1, TT-01, and others. 

Reach out @ Vitiligo Pipeline: Novel therapies and Emerging technologies 

Table of Contents 

1 Report Introduction
2 Vitiligo Disease Overview
3 Vitiligo Current Treatment Patterns
4 DelveInsight's Analytical Perspective
5 Vitiligo Therapeutic Assessment
6 Vitiligo Late Stage Products (Phase-III)
7 Vitiligo Mid Stage Products (Phase-II)
8 Early Stage Vitiligo Products (Phase-I)
9 Pre-clinical Products and Discovery Stage Products
10 Inactive Products
11 Dormant Products
12 Vitiligo Discontinued Products
13 Vitiligo Therapeutics Pipeline Analysis
14 Inactive Vitiligo Pipeline Products 
15 Vitiligo  Product Profiles
16 Vitiligo  Key Companies
17 Vitiligo  Key Products
18 Dormant and Discontinued Products
19 Vitiligo  Unmet Needs
20 Vitiligo  Future Perspectives
21 Analyst Review  
22 Appendix
23  Report Methodology
24 Consulting Services
25 Disclaimer
26 About DelveInsight

Learn more about the report offerings @ Vitiligo Emerging Therapies, Treatments and Ongoing Clinical Trials 

Related Reports

Vitiligo Market
DelveInsight's "Vitiligo Market Insights, Epidemiology, and Market Forecast-2030" report.

Vitiligo Epidemiology Forecast
DelveInsight's 'Vitiligo Epidemiology Forecast to 2030' report.

Dyschromia Market
DelveInsight's "Dyschromia Market Insights, Epidemiology, and Market Forecast-2030" report. 

Dystrophic Epidermolysis Bullosa Market
DelveInsight's "Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2030" report.

Exanthema Market
DelveInsight's "Exanthema Market Insights, Epidemiology, and Market Forecast-2030" report.

Eczema Market
DelveInsight's "Eczema Market Insights, Epidemiology, and Market Forecast-2030" report.

Generalized Pustular Psoriasis Market
DelveInsight's "Generalized Pustular Psoriasis Market Insights, Epidemiology, and Market Forecast-2030" report.

Related Posts 
Most Common Foods Allergies
Atopic Dermatitis Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 


Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com

Primary Logo

View Comments and Join the Discussion!
 

Latest Ratings

StockFirmActionPT
WEXMorgan StanleyMaintains195.0
VRTXMorgan StanleyMaintains202.0
VCYTMorgan StanleyMaintains42.0
VCMorgan StanleyMaintains75.0
URIMorgan StanleyMaintains268.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com